Resomelagon is under clinical development by SynAct Pharma and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Nearly 200 nations at the Cop28 climate summit in Dubai agreed to the deal, which calls on them to "transition away" from ... who had called for the term "phase out" of fossil fuels to be used ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

Deconfined quantum criticality represents a novel class of phase transitions that fall outside ... material candidates show a weakly-first order transition. Here the authors introduce a Nordic ...